KBI in the News | AdAlta secures key manufacturing agreements for AD-214

Picture of Admin Admin Aug 28, 2018 9:27:01 AM

News

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

MELBOURNE Australia, 5 June 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development, is pleased to announce that it has secured agreements critical to the development of its lead therapeutic program, AD-214. Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing services.

Read Full Press Release from AdAlta (PDF)

KBI Biopharma Awarded as Global Leader in Biologics Manufacturing

Durham, North Carolina (April 3, 2025) – KBI Biopharma, a JSR Life Sciences Company and leading global contract development and manufacturing...

KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate

KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology Durham,...

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization...